期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

应重视上市后药物安全性的循证医学再评价——罗非昔布召回的意义 被引量：3

Evidence-Based Safety Reassessment of Post Marketed Drug — Importance of Recall of Refecoxib
下载PDF
导出
摘要 本文通过回顾罗非昔布导致心脑血管疾病发生率增加而被召回这一事件 ,提出现有上市后药物安全性监测的问题和对策。 This article aims to review the recall of refecoxib which increases the incidence of cardiovascular and cerebrovascular diseases and to find the methods to solve problems in post marked monitoring of drug safety.
作者 胡大一 杨进刚
机构地区 首都医科大学北京同仁医院心血管中心
出处 《中国循证医学杂志》 CSCD 2005年第2期94-96,共3页 Chinese Journal of Evidence-based Medicine
关键词 罗非昔布 药物不良反应 上市后药物安全性监测 Refecoxib Adverse reaction Post marked monitoring of drug safety
分类号 F416.7 [经济管理—产业经济]
  • 相关文献

参考文献11

  • 1Hunt ILH, Bowen B, Mortensen EIL, Simon TJ, James C, Cagliola A, Quan H, Bolognese JA. A randomized trial measuring fecal blood loss after treatment with refecoxib, ibuprofen, or placebo in healthy subjects [J ]. Am J Med, 2000 ; 109 (3) : 201 - 206.
  • 2Department of Health and Ageing. Consumer level recall of arthritis drug[ R]. Available from URL: http ://www. tga. gov. att/media/2004/040930_vioxx. htm, 2004; 10.
  • 3Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM,Naglie G, Peter C Austin, Andreas Laupacis. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs[J]. BMJ, 2002:325(7 365) : 624.
  • 4Topol EJ. Failing the public health-Refecoxib, Merck, and the FDA[J]. New Eng J Med, 2004; 1 466(351): 1 707-1709.
  • 5Khan KN, Paulson SK, Verburg KM, Lefkowith JB, Maziasz TJ.Pharmacology of Cyclooxygenase-2 inhibition in the kidney[J]. Kidhey Int, 2002; 61(4): 1 210-1 219.
  • 6Layton D, Riley J, Wilton LV, Shakir SA. Safety profile of refecoxib as used in general practice in England: results of a prescription-event monitoring study[J].Br J Clin Pharmacol, 2003; 55 (23) :166 - 174.
  • 7Fendrick AM, Garabedian-Ruffalo SM. A clinician's guide to the selection of NSAID therapy[J]. P & T, 2002; 53(27) : 579 - 582.
  • 8Cox ER, Frisse M, Behm A, Fairman KA. Over-the-counter pain reliever and aspirin me within a sample of long-term cyclooxygenase--2 users[J]. Arch Intern Med, 2004; 456(164) : 1 243 - 1 246.
  • 9Chart FK, Hung LC, Suen BY. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis[J]. N Engl J Med, 2002; 847(347) : 2 104-2 110.
  • 10Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal anti-inflammatory drugs, including cyclooxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomized placebo controlled trials[J]. BMJ, 2004; 329(7 478) : 1 317.

同被引文献29

引证文献3

二级引证文献31

中国循证医学杂志
2005年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部